Monday, December 18, 2006 8:30:00 AM PDT | VentureDeal Staff
MA -- Cequent Pharmaceuticals today
announced the closing of a $6 million series A round of financing.
The company licensed technology from the Beth Israel
Center & Harvard Medical School
which allows for RNAi-based treatments to be carried by bacteria into targeted
areas deep within the human body, without surgery.
Cequent is in pre-clinical stage and is focusing its efforts on
gastrointestinal diseases, including familial polyposis, inflammatory bowel
disease and colon cancer.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
Email Sign Up
© 2016 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.